First-use risks.
Rowe
Timothy C
TC
D000726:Androgen Antagonists / Q000009:adverse effects*; D002170:Canada / Q000453:epidemiology; D003257:Consumer Product Safety; D017373:Cyproterone Acetate / Q000009:adverse effects*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000453:epidemiology
D000726:Androgen Antagonists; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination